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Aim: To describe treatment and referral patterns and National Health Service resource
use in patients with chronic pain associated with low back pain or osteoarthritis, from a
Primary Care perspective. Background: Osteoarthritis and low back pain are the two
commonest debilitating causes of chronic pain, with high health and social costs, and
particularly important in primary care. Understanding current practice and resource use
in their management will inform health service and educational requirements and the
design and optimisation of future care.Method: Multi-centre, retrospective, descriptive
study of adults (⩾18 years) with chronic pain arising from low back pain or osteoarthritis,
identiﬁed through primary care records. Five general practices in Scotland, England
(two), Northern Ireland and Wales. All patients with a diagnosis of low back pain or
osteoarthritis made on or before 01/09/2006 who had received three or more prescrip-
tions for pain medication were identiﬁed and a sub-sample randomly selected then
consented to an in-depth reviewof theirmedical records (n = 264). Data onmanagement
of chronic painwere collected retrospectively from patients’ records for three years from
diagnosis (‘newly diagnosed’ patients) or for the most recent three years (‘established’
patients). Findings: Patients received a wide variety of painmedications with no overall
common prescribing pattern. GP visits represented the majority of the resource use and
‘newly diagnosed’ patients were signiﬁcantly more likely to visit their GP for pain manage-
ment than ‘established’ patients. Although ‘newly diagnosed’ patients had more referrals
outside the GP practice, the number of visits to secondary care for pain management was
similar for both groups.Conclusion: This retrospective study conﬁrmed the complexity of
managing these causes of chronic pain and the associated high resource use. It provides an
in-depth picture of prescribing and referral patterns and of resource use.
Key words: analgesic prescribing; low back pain; osteoarthritis; pain; primary
healthcare; referral and consultations
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Introduction
The International Association for the Study
of Pain deﬁnes chronic pain as ‘pain that has
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persisted beyond normal tissue healing time’, and
in the absence of rigorous markers for normal
tissue healing time, a period of three months is
usually accepted as the point at which pain can be
classiﬁed as chronic (Merskey and Bogduk, 1994).
Approximately 20% of the adult population in
Europe have been found to be suffering from
chronic pain (Breivik et al., 2006), with over 5%
experiencing severe, disabling pain (Smith et al.,
2001). The management of chronic pain represents
a signiﬁcant burden to the National Health Service
(NHS); it has been estimated that chronic pain
accounts for 4.6 million general practice appoint-
ments in the United Kingdom each year, at a cost
of £69 million, equivalent to 793 full-time general
practitioners (GPs) (Belsey, 2002). Osteoarthritis
(OA) and low back pain (LBP) contribute sig-
niﬁcantly to the number of people in the United
Kingdom with chronic pain, together accounting
for more than half of all cases (Elliott et al., 1999)
and with the ageing population, the burden is
likely to increase over the coming years.
There is little rigorous evidence to guide the
day-to-management of chronic pain in primary
care (Smith et al., 2010), and outside the clinical
trial setting, current primary care treatment pat-
terns and referral rates in chronic pain management
are not well understood. It is therefore difﬁcult to
target resources and identify educational needs for
this major primary care disease burden, and to
quantify ways in which pain management may be
improved. This study aimed to describe the man-
agement of patients with OA and chronic LBP in
real-world primary care practice and to quantify
the NHS resource utilisation associated with the
management of these conditions.
Methods
Design
A multi-centre, retrospective, descriptive
observational study.
Setting
Five general practices were purposively selected
[Scotland, England (two), Wales and Northern
Ireland], to provide a range of practice size
(5200–18 000 patients/practice), number of GPs
per practice (3–11 GPs/practice; total 34 GPs) and
a mixture of urban and rural locations and
socioeconomic groups of patients. One GP in each
practice was identiﬁed as a Principal Investigator
(PI) on the basis of his interest in chronic pain.
Patient identiﬁcation
Using the practice database, the PI at each site
identiﬁed all patients with a diagnosis of LBP or
OA (based on Read coding) on or before 01/09/
2006, aged ⩾ 18 years, without a diagnosis of
cancer-related pain, and who had received three or
more prescriptions for pain medication. Of these,
250 patients at each practice were randomly
selected and invited to consent to the study and
have a researcher review their medical records.
We identiﬁed individuals with clinically signiﬁcant
chronic pain (Smith et al., 2001), as those who had
received at least three prescriptions for any pain
medication since diagnosis, based on a previously
validated search protocol (McDermott et al.,
2006). Consenting patients who met the inclusion
criteria of having a diagnosis of OA or LBP and
who had received at least three prescriptions for
any pain medication since diagnosis, were there-
fore included in the study (n = 264).
Data collection and analysis
Data were collected from two cohorts of patients:
in ‘newly diagnosed’ patients (ie OA or LBP diag-
nosed between 01/09/2004 and 01/09/2006) data
from the ﬁrst three years after diagnosis were
collected to describe the initial stages of manage-
ment; in ‘established disease’ patients (ie diagnosed
before 01/09/2004) data from the most recent three
years were collected to provide data on recent pain
management, later in the course of the condition.
Anonymised data relating to analgesic pre-
scriptions, consultations, and referrals between
01/09/2004 and 01/09/2009 were collected from
primary care paper records and electronic systems
betweenApril and July 2010 by researchers working
to data collection guidelines.
Data were collected on pain medications pre-
scribed at least once by GPs or Nurse Prescribers.
The drugs included analgesics, antidepressants and
anti-epileptics where the clinical record clearly
showed that the prescription was for pain.
Opioid analgesics were classiﬁed as ‘strong’
or ‘weak’ according to the British National
Formulary (British Medical Association and the
Royal Pharmaceutical Society of Great Britain,
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2010). Weak opioids identiﬁed during the study
included codeine, dihydrocodeine, meptazinol and
tramadol, and ‘strong’ included buprenorphine,
fentanyl, morphine and oxycodone.
All visits to the GP practice were recorded dur-
ing the study period. Visits were classiﬁed as ‘pain
related’ or ‘non-pain related’ according to the pre-
sence or absence of reference to pain in the clinical
record.
All records of patient referrals that occurred
within the study period, from the GP to secondary
care or non-NHS services for pain management
were noted.
Non-drug interventions were deﬁned as inter-
ventions related to the management of pain but
did not involve the administration of medication,
and were recorded in the notes as recommended
or administered to the patient.
Co-prescribed medication were deﬁned as
medication to prevent or manage unwanted effects
of pain medication (eg laxatives, anti-emetics,
medication for indigestion).
Analysis was undertaken in MS Excel and SPSS
for Windows. Statistical analysis employed the Fisher
Exact Test of Probability and the Kruskal–Wallis test.
Ethical approval was obtained from Outer
South East London Research Ethics Committee
(09/HO805/42) and NHS R&D approval was
obtained in each study area.
Results
Study sample
From a total of 1250 identiﬁed patients, 606 (49%)
consented and 264 (44%) of these were eligible.
Reasons for ineligibility were: at least three pre-
scriptions not issued (n = 140), and incorrect or late
completion of the consent form (n = 202).
The sample was 71% female and the mean cur-
rent age was 62 years in ‘newly diagnosed’, and
66 years in ‘established’ patients (Table 1). Almost
two-thirds (64%) of patients had OA, although
among ‘newly diagnosed’ patients the split
between OA and LBP was more even (55% OA).
OA or LBP was diagnosed a mean of 6.7 years
before data collection (one year for ‘newly
diagnosed’ and 8.1 years for ‘established’ patients).
No patients in the study sample had a recorded
diagnosis of both OA and LBP. The earliest date
of diagnosis was 1977.
Pain treatment
Prescribed medication
Most patients (62%) were prescribed ﬁve or
fewer different drugs at least once for pain man-
agement over the three-year study period and a
signiﬁcant minority (38%) received six or more
different drugs (Figure 1). Similarly, while many
patients (45%) had received no co-prescribed
drugs, most (49%) received between one and
three drugs prescribed for unwanted effects of pain
medication. Differences in these proportions
between ‘newly diagnosed’ and ‘established’ were
not statistically signiﬁcant.
‘Weak’ opioids were prescribed to 161 (61%)
patients and themajority of these patients received
a tramadol product (122, 46%; Table 2). Com-
pound analgesics containing ‘weak’ opioids and
paracetamol were prescribed to 194 (73%)
patients. Almost all patients (96%) received an
opioid containing analgesic within the three-year
study period and 17% of patients (n = 44) were
prescribed at least one type of ‘strong opioid’:
[n = 7 (13%) ‘newly diagnosed’ and n = 37 (18%)
Table 1 Description of study sample and drug treatments for pain
Newly diagnosed
(n = 53) [N (%)]
Established
(n = 211) [N (%)]
All (n = 264)
[N (%)]
Mean current age (years) 62 66 65
Malea 15 (28) 60 (29) 75 (29)
Female 38 (72) 150 (71) 188 (71)
Low back pain 24 (45) 72 (34) 96 (36)
Osteoarthritis pain 29 (55) 139 (66) 168 (64)
Mean time since diagnosis of chronic pain (years) 1.0 8.1 6.7
a Sex of one patient not recorded.
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‘established’ patients]: 26 (10%) received bupre-
norphine, 14 (5%) morphine, 10 (4%) fentanyl
patch and 9 (4%) oxycodone (Table 3).
Oral non-steroidal anti-inﬂammatory drugs
(NSAIDs) were prescribed to 58% of patients [35
(66%) ‘newly diagnosed’ and 118 (56%) ‘established’
patients]. Adjuvant analgesic drugs such as tricyclic
antidepressants and anti-epileptics were prescribed
for 154 patients (58%). The most prevalent adjuvant
analgesic prescribed was amitriptyline, to 80 (30%)
patients, followed by pregabalin and gabapentin to
29 (11%) and 26 (10%) of patients, respectively.
Co-prescribed medication to prevent or manage
unwanted effects of pain medication was pre-
scribed to 145 (55%) patients, including laxatives
(41%), gastro-protective agents (48%) and anti-
emetics (11%) (Table 3). Rates of co-prescribing
were similar among ‘newly diagnosed’ and ‘estab-
lished’ patients.
Reasons for changing pain medication were
documented in only 457 (21%) of the 2188 recor-
ded changes over the study period.
Non-drug interventions
Non-drug interventions such as physiotherapy
and acupuncture were prescribed for 34 (64%)
‘newly diagnosed’ and 86 (41%) ‘established’
patients during the three-year study period.
Overall, 105 (40%) patients were recorded as
receiving physiotherapy during the study period
[29 (55%) ‘newly diagnosed’ and 76 (35%)
‘established’]. Exercises were recommended and
recorded by the GP for 6% overall (17% ‘newly
diagnosed’, 4% ‘established’). Acupuncture was
similarly recommended and recorded for 6%
overall (8% ‘newly diagnosed’, 6% ‘established’)
and transcutaneous electrical nerve stimulation
for 3% overall (4% ‘newly diagnosed’, 2%
‘established’). One episode each of psychotherapy,
occupational therapy, osteopathy and heat pads
was recorded.
Referral patterns
Table 4 shows the number of patients referred
outside the GP practice for investigation, treat-
ment or specialist opinion during the study period,
and the specialties to which they were referred.
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Figure 1 Number of pain medications prescribed in
three years
Table 2 Drug treatments for pain
Newly diagnosed
(n = 53) [N (%)]
Established
(n = 211) [N (%)]
All (n = 264)
[N (%)]
Non-opioid 48 (91) 181 (86) 229 (87)
Paracetamol 30 (57) 100 (47) 130 (49)
Systemic NSAID 35 (66) 118 (56) 153 (58)
Topical NSAID 16 (30) 68 (32) 84 (32)
COX-II inhibitor 6 (11) 15 (7) 21 (8)
Other non-opioid analgesic 4 (8) 8 (4) 12 (5)
Opioid 53 (100) 201 (95) 254 (96)
Compound analgesic (containing weak opioid) 41 (77) 153 (73) 194 (73)
Weak opioid analgesic 35 (66) 126 (60) 161 (61)
Strong opioid analgesic 7 (13) 37 (18) 44 (17)
Adjuvant analgesic drugs (eg amitriptyline and pregabalin) 33 (62) 121 (57) 154 (58)
NSAID = non-steroidal anti-inﬂammatory drugs; COX-II = cyclooxygenase-II.
All drugs grouped by British National Formulary (British Medical Association and the Royal Pharmaceutical Society of
Great Britain, 2010) classiﬁcation.
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Eighty-one per cent of ‘newly diagnosed’ patients
and 68% of ‘established’ patients were referred
elsewhere for pain management, with a sig-
niﬁcantly higher referral rate for ‘newly diagnosed’
patients [0.77 versus 0.62 referrals/patient/year
(P< 0.01)]. However, ‘established’ patients were
referred to a wider range of specialties and provi-
ders. In ‘newly diagnosed’ patients where data were
available, the mean (SD) time from diagnosis to
ﬁrst referral was 9.4 (10.0) months (range 0–34.3).
Table 3 Opioid and co-prescribed medications
Newly diagnosed
(n = 53) [N (%)]
Established
(n = 211) [N (%)]
All (n = 264)
[N (%)]
Strong opioid analgesic 7 (13) 37 (18) 44 (17)
Buprenorphinea 3 (6) 23 (11) 26 (10)
Morphine 3 (6) 11 (5) 14 (5)
Fentanyl patch 1 (2) 9 (4) 10 (4)
Oxycodone 0 9 (4) 9 (4)
Weak opioid analgesic 35 (66) 126 (60) 161 (61)
Tramadolb 26 (49) 84 (40) 110 (42)
Tramadol and paracetamol – 12 (6) 12 (4)
Codeine 9 (17) 27 (13) 36 (14)
Dihydrocodeine 10 (19) 24 (11) 34 (13)
Meptazinol 0 1 (0.5) 1 (0.4)
Co-prescribed medication 31 (58) 114 (54) 145 (55)
Laxative 27 (51) 81 (38) 108 (41)
Gastro-protective agent 27 (51) 101 (48) 128 (48)
Anti-emetic 4 (8) 26 (12) 30 (11)
Opioids have been classiﬁed according to British National Formulary (BNF) (British Medical Association and the Royal
Pharmaceutical Society of Great Britain, 2010).
a Buprenorphine is classiﬁed as a strong opioid analgesic, but it is recognised that low dose patches may be included
and would more appropriately be classiﬁed as weak opioids. As dose was not recorded in this study drugs cannot be
presented by strength.
b Tramadol and Tramacet are classiﬁed as weak opioids in BNF 59; it is recognised that tramadol is only considered a
strong opioid at high doses (⩾400mg daily), also that the maximum recommended daily dose of Tramacet includes
300mg/day of tramadol.
Table 4 Referrals for pain management
Referral Newly diagnosed
(n = 53) [N (%)]
Established
(n = 211) [N (%)]
All (n = 264)
[N (%)]
No referral 10 (19) 67 (32) 77 (29)
Referral 43 (81) 144 (68) 187 (71)
Therapy and investigation
Physiotherapy 29 (55) 74 (35) 103 (40)
Radiology 22 (42) 77 (37) 99 (37)
Secondary care specialist
Orthopaedics 20 (38) 60 (28) 80 (30)
Pain clinic 2 (4) 19 (9) 21 (8)
Rheumatology 7 (13) 9 (4) 16 (6)
Neurosurgery 1 (2) 8 (4) 9 (3)
Neurology 0 6 (3) 6 (2)
Other referral sitesa 16 (30) 95 (45) 111 (42)
Referral rate 0.77 referrals/patient/year 0.62 referrals/patient/year
a Other referral sites included: musculoskeletal clinic, podiatry, geriatrics, intermediate care, acupuncture, anaesthetics,
counselling, day procedure unit, falls prevention, foot and ankle service, Nurse, occupational therapy, pathology, urology,
mental health.
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Physiotherapy was the most common referral
(55% ‘newly diagnosed’ patients) with a mean of
0.26 referrals/patient/year over the ﬁrst three years
since diagnosis.
Resource use
NHS resources in primary and secondary care
were heavily used by these patients (Table 5).
Most GP practice visits for pain management
(67%) were with a GP, 29% were with a Practice
Nurse and 4% were with other practice staff.
‘Newly diagnosed’ patients visited their GP
practice signiﬁcantly more frequently for pain-
related reasons than did ‘established’ patients,
both in the ﬁrst year after diagnosis (median 4
visits) and in the average per year (3.7) among the
‘newly diagnosed’ patients, compared with 2.3 per
year among ‘established’ patients (P< 0.001).
(Mean pain-related GP visits per year: 3.9 for
‘newly diagnosed’ and 3.0 for ‘established’.)
For non-pain-related visits, ‘established’ patients
visited their practice signiﬁcantly more frequently
than ‘newly diagnosed’ patient. This was true in both
the ﬁrst year (median 5.0 visits) and the average per
year (6.3), compared with 8.3 per year among
‘established’ patients (P<0.005). (Mean non-pain-
related GP visits per year were 7.7 for ‘newly diag-
nosed’ and 9.4 for ‘established’ patients.)
Secondary care visits were less frequent than
primary care visits. Outpatient visits to specialists
were the most common, with no differences in
frequency found between ‘newly diagnosed’ and
‘established’ patients.
Discussion
This retrospective multi-centre study was designed to
gather data on real-world clinical practice across the
United Kingdom, and in particular to describe cur-
rent treatment, referral patterns and NHS resource
use associated with the management of chronic pain
in OA and LBP. This is the ﬁrst systematic recording
of themanagement of chronic pain in routine general
practice and provides a picture of the impact of
chronic pain on primary care practice. The ﬁndings
highlight both the large resource requirement among
this group in terms of prescribing, consultation and
referral, and the wide range of practice.
Of course, the results are not representative of
all GP practices in the United Kingdom as patient Ta
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populations and pain management vary greatly
between practices and only ﬁve practices partici-
pated in the study. Each practice had a GP who
was relatively well informed in pain-related issues,
which may have inﬂuenced their approach to
treating pain. These GPs may have a more proac-
tive and conﬁdent approach to prescribing and
referral of patients than GPs without this interest.
Nevertheless, the study sample was selected from
all the patients within these practices, managed by
all 34 GPs, not just those managed by the GP with
the interest in pain, and their overall inﬂuence on
the results is likely to be very small.
In its retrospective design, the study data quality
relied on the completeness of primary care clinical
records. In addition, information on non-NHS
treatments, for example, over-the-counter medi-
cations, complementary therapies and other pri-
vate appointments were not available. It was not
possible to identify all patients with chronic pain
from clinical records, as there are no primary care
registers or Read codes for patients with chronic
pain. It is therefore unclear what proportion of OA
and LBP patients with chronic pain were excluded
from this study, and how their prescribing and
referral patterns differed from those we included.
It has previously been shown that seeking of
treatment and use of analgesics identiﬁes those
with the most signiﬁcant chronic pain (Smith et al.,
2001), and it is likely that we have included those
of most importance to the health services. Breivik
et al. (2006) found that 78% of all individuals
reporting chronic pain had received a prescription
of analgesic medication. We only included those
with LBP and OA for logistical reasons, and while
our ﬁndings cannot be directly extrapolated to
those with other conditions, it is likely that they
will be similar for other musculoskeletal causes of
chronic pain.
The number of different pain medications given
to patients in this study suggests that management
of chronic pain associated with OA or LBP is
complex in many patients, often involving a trial
of several different analgesics and combinations
with adjuvant pain medication, non-drug therapies,
and in many cases, referral for specialist opinion,
resulting in individualised patient management. The
large proportion of patients receiving co-prescribed
medication suggests that avoiding unwanted effects of
pain medication is also important in the management
of these patients. There is no evidence of a standard
approach to chronic pain management in primary
care. This highly individualised care seen in this study
is in line with guidance from The National Institute
for Health and Clinical Excellence (NICE, 2008;
2009; 2010) but does involve close patient manage-
ment that the resource use data from this study
also shows.
Patients with multi-morbidities also often
require close management to avoid adverse effects
from polypharmacy. NSAIDs and opioids are
the ‘mainstay’ of chronic pain management and
are included in the top 10 medication most asso-
ciated with adverse-drug-reaction related hospital
admissions (Pirmohamed et al., 2004). Describing
the presence of co-morbidities was beyond the
scope of this study, but a high prevalence of multi-
morbidities in adult and older adult patients in
primary care has recently been described; 87% of
patients with painful conditions including back
pain and OA had at least one co-morbid condition,
46% had three or more (Barnett et al., 2012).
In view of the high prevalence of both chronic pain
and multi-morbidity, the complexity we have
described in the management of chronic pain
alone, and the poor tolerability of many
pain medications, it would seem clear that robust
guidelines for individualised care should be
developed for primary care, to minimise morbidity
and maximise patients’ quality of life. Ideally,
these would address chronic pain in the context of
its co-morbidities (Guthrie et al., 2012).
The current relevant guidance emphasises the
importance of identifying early the needs of
patients with chronic pain, establishing individual
management plans, prescribing according to
standard approaches (where these are available),
reviewing patients early and frequently, and
referring for specialist opinion in the event of non-
response. This study suggests that while treatment
may be individualised, many patients are not
referred to specialists until relatively late in their
clinical course, perhaps leading to a delay in
providing optimal treatment.
The activity in pain management is greater
among the ‘newly diagnosed’ patients as seen in
the pattern of referrals to specialists, where ‘newly
diagnosed’ patients were more likely to be referred
than ‘established’ patients (81 versus 68%) with a
signiﬁcantly higher referral rate for pain manage-
ment in the ﬁrst three years since diagnosis (0.77
versus 0.62 referrals/year). Further development
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of evidence-based referral guidelines would be
helpful to guide the long-term management of this
chronic condition and deﬁning what constitutes
appropriate levels of referral for all stages of
chronic pain management.
Only 8% of all patients in this study were referred
to a pain clinic, demonstrating that the majority of
painmanagement is delivered byGPs in primary care.
‘Newly diagnosed’ patients attended their GP surgery
for pain-related visits signiﬁcantly more often than
‘established’ patients, with the most visits occurring in
the ﬁrst year. Further study is needed to determine to
what extent the reduction in visit frequency over time
is associated with well-controlled pain, requiring only
infrequent monitoring, compared with perceived
exhaustion of therapeutic options and acceptance by
patients of a degree of uncontrolled pain.
The opposite trend was found for non-pain-
related visits with ‘established’ patients attending
their GP surgery signiﬁcantly more often than
‘newly diagnosed’ patients. While this may reﬂect
the older age of the ‘established’ group of patients,
and consequent co-morbidities, further study is
needed to understand the nature of the non-pain-
related visits and relationship, if any, with control
and manifestation of pain.
As may be expected, GPs appeared to broadly
follow the ‘analgesic ladder’ approach to analgesic
prescribing. More than half the patients (58%)
received NSAIDs. Whilst NSAID use is recom-
mended for OA and LBP (NICE, 2008; 2009), their
effectiveness in controlling pain in OA has been
shown to be limited to around two to four weeks in
most patients (Scott et al., 2000) and there is less
evidence of their long-term effectiveness. The low-
est effective dose of NSAID should be prescribed
for the shortest period of time to control symptoms
and the need for long-term treatment should be
reviewed periodically (NICE, 2008; 2009; British
Medical Association and the Royal Pharmaceutical
Society of Great Britain, 2012). Their long-term use
in older adults should be limited (British Medical
Association and the Royal Pharmaceutical Society
of Great Britain, 2012).
Most patients (87%) were prescribed non-
opioid analgesics and compound analgesics con-
taining a ‘weak’ opioid (73%). However, in com-
parison, the number of patients receiving ‘strong’
opioids was considerably lower (17%). There is
good evidence for the safety and effectiveness of
strong opioids in non-malignant pain (Kalso et al.,
2004), and they are agreed to have a role in the
early management of back pain (Kalso et al., 2005),
but it was difﬁcult to judge how much their use in
this study was consistent with the good practice
consensus guidance now available from The
British Pain Society (2010). Among other impor-
tant features, these guidelines recommend full and
early discussions about potential side effects; close
monitoring of dose, effects and possible misuse;
their use as part of a wider treatment plan incor-
porating physical, social and psychological dimen-
sions; the use of modiﬁed release preparations
where possible; and early referral to specialists
in the event of problem drug use. This relative
low use of strong opioids may conﬁrm previous
ﬁndings of GPs’ reluctance to prescribe ‘strong’
opioids because of concerns about effects on
patient behaviour, professional competency con-
cerns and degree of belief in opioid effectiveness in
chronic pain (McCracken et al., 2008).
The widespread prescription of weak opioids
was notable, despite limited evidence of their
added beneﬁt over simple analgesics (Li Wan Po
and Zhang, 1997). The strategy for reviewing
response to medication and adjusting accordingly
was not well documented so the opportunity to
transfer valuable patient information between
healthcare professionals was lost. The results of
this study suggest there is a need for additional GP
education in the use of analgesics for the long-term
management of chronic pain.
There is increasing focus on non-pharmacological
approaches to managing chronic pain, and some
recent studies have found some of these to be
effective in primary care (Heymans et al., 2004;
Von Korff et al., 2005; Van Tulder et al., 2006). We
found that GPs were reasonably good at referring
for these, though might have done so more often.
Dissemination and implementation of effective
non-pharmacological interventions is an important
approach in primary care, in addition to prescribing.
The Scottish Intercollegiate Guidelines Network
(SIGN) new guidelines on the Management of
Chronic Pain address this (SIGN, 2013).
Conclusion
These results from a retrospective study of a
cohort of patients with chronic OA pain or LBP
offer a useful picture, previously unavailable, of
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the management of this resource-intensive group
of patients. It seems that prescribing is complex,
often involving the management of side effects,
and does not conform to a particular pattern. The
further development of evidence-based guidelines
for primary care treatment and referral for chronic
pain could be of great beneﬁt. The need for further
research in primary care is therefore apparent, and
so too is the need for more education on chronic
pain for primary care professionals.
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